You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 13, 2024

Details for Patent: 11,072,577

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,072,577 protect, and when does it expire?

Patent 11,072,577 protects CUVRIOR and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.

Summary for Patent: 11,072,577

Title:	Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
Abstract:	The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3.+-.0.1.degree.2.theta. and Raman shifts 943, 1173, 1527 and 1612.+-.5 cm.sup.-1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Inventor(s):	Morley; Timothy James (Harrogate, GB), Lawrence; Ronnie Maxwell (Upper Gravenhurst, GB), Amin; Naseem (London, GB)
Assignee:	Orphalan S.A. (Paris, FR)
Application Number:	17/171,358
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,072,577

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,072,577

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	18290048	May 4, 2018

International Family Members for US Patent 11,072,577

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	115080	⤷ Try a Trial
Australia	2019263969	⤷ Try a Trial
Brazil	112020018451	⤷ Try a Trial
Canada	3096423	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.